EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
8.0301
8.0750
年范围
7.7400
11.4600
日变化
+0.37%
每月变动
+0.25%
6个月变化
-24.81%
年变化
-24.81%
前一天收盘价
8.0300
开盘价
8.0575
最低价
8.0301
High
8.0750
交易量
159
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry 药品制造—专业与仿制药
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
13.29
市销率
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

新闻